FDA Drug recall D-0770-2026
Carbamazepine Tablets, USP, 200mg, 1000 count bottles, Rx only, Manufactured by: Taro Pharmaceutical Industries Ltd., Haifa Bay, Israel 262…
- FDA Drug
- Class II
- ongoing
- Published 2026-08-26
On 2026-08-26 the FDA classified a Class II recall of Carbamazepine Tablets, USP, 200mg, 1000 count bottles, Rx only, Manufactured by: Taro Pharmaceutical Industries Ltd., Haifa Bay, Israel 262… by Sun Pharmaceutical Industries, citing CGMP Deviations; black spots found on tablets from burnt excipient during manufacturing.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0770-2026 |
| Classification | Class II |
| Status | ongoing |
| Initiated | 2026-08-03 |
| Published | 2026-08-26 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Sun Pharmaceutical Industries |
| Distribution | US |
Product
Carbamazepine Tablets, USP, 200mg, 1000 count bottles, Rx only, Manufactured by: Taro Pharmaceutical Industries Ltd., Haifa Bay, Israel 2624761, Distributed by: Taro Pharmaceuticals USA, Inc., Hawthorne, NY 10532, NDC 51672-4005-3.
Reason
CGMP Deviations; black spots found on tablets from burnt excipient during manufacturing
Identifiers
| ndc | 51672-4041-1 |
|---|---|
| ndc | 51672-4041-2 |
| ndc | 51672-4041-9 |
| ndc | 51672-4041-0 |
| ndc | 51672-4050-1 |
| ndc | 51672-4005-1 |
| ndc | 51672-4005-2 |
| ndc | 51672-4005-3 |
| ndc | 51672-4123-6 |
| ndc | 51672-4123-1 |
| ndc | 51672-4123-3 |
| ndc | 51672-4124-6 |
| ndc | 51672-4124-1 |
| ndc | 51672-4124-3 |
| ndc | 51672-4125-6 |
| ndc | 51672-4125-1 |
| ndc | 51672-4125-3 |
| ndc | 51672-4047-9 |
| ndc | 51672-4047-4 |
| code_info | Lot # AD94033, Exp Date: 5/31/2028. |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0770-2026%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.